Document Detail


Elucidating the molecular basis of action of a classic drug: guanidine compounds as inhibitors of voltage-gated potassium channels.
MedLine Citation:
PMID:  21926190     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Guanidine and its alkyl analogs stimulate the neuromuscular junction presynaptically by inhibiting voltage-gated potassium (Kv) channels, leading to enhanced release of acetylcholine in the synaptic cleft. This stimulatory effect of guanidine underlies its use in the therapy for the neuromuscular diseases myasthenic syndrome of Lambert-Eaton and botulism. The therapeutic use of guanidine is limited, however, because of side effects that accompany its administration. Therefore, the design of guanidine analogs with improved therapeutic indices is desirable. Progress toward this goal is hindered by the lack of knowledge of the mechanism by which these molecules inhibit Kv channels. Here we examine an array of possible mechanisms, including charge screening, disruption of the protein-lipid interfaces, direct interaction with the voltage sensors, and pore-binding. Our results demonstrate that guanidines bind within the intracellular pore of the channel and perturb a hydrophobic subunit interface to stabilize a closed state of the channel. This mechanism provides a foundation for the design of guanidine analogs for the therapeutic intervention of neuromuscular diseases.
Authors:
Jeet Kalia; Kenton J Swartz
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural     Date:  2011-09-16
Journal Detail:
Title:  Molecular pharmacology     Volume:  80     ISSN:  1521-0111     ISO Abbreviation:  Mol. Pharmacol.     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2011-11-21     Completed Date:  2012-01-12     Revised Date:  2013-05-23    
Medline Journal Info:
Nlm Unique ID:  0035623     Medline TA:  Mol Pharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1085-95     Citation Subset:  IM    
Affiliation:
Porter Neuroscience Research Center, Molecular Physiology and Biophysics Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Female
Guanidine / metabolism,  pharmacology*
Potassium Channel Blockers / metabolism,  pharmacology*
Potassium Channels, Voltage-Gated / antagonists & inhibitors,  metabolism
Protein Binding / physiology
Shaker Superfamily of Potassium Channels / antagonists & inhibitors*,  metabolism
Xenopus laevis
Chemical
Reg. No./Substance:
0/Potassium Channel Blockers; 0/Potassium Channels, Voltage-Gated; 0/Shaker Superfamily of Potassium Channels; 113-00-8/Guanidine
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Tailored cognitive-behavioural therapy and exercise training improves the physical fitness of patien...
Next Document:  Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiog...